NCT07024706 · AstraZeneca
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
(MAVRiC)
What this study is about
This study will evaluate the effectiveness and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
View original scientific description
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Participant must be ≥ 18 years at the time of signing informed consent.
- Diagnosis of CLL/SLL according to iwCLL guidelines 2018 (Hallek et al. 2018)
- Participants must have received first line treatment with fixed duration covalent BTKi plus BCL2i therapy (± obinutuzumab) with a response ≥ PR (i.e., CR, CRi, nPR, or PR) with a minimum of 2 years since the end of the prior 1L treatment.
- The following data must be available or at least the appropriate samples drawn/acquired prior to dosing:
- IGHV (mutated vs. unmutated)
- del(17p) (present or absent)
- TP53 mutation (present or absent)
- ECOG performance status 0, 1 or 2
- Adequate organ and bone marrow (BM) function. Main
Exclusion criteria
- Any evidence of diseases that, in the investigator's opinion, makes it undesirable for patient to participate in the study.
- Significant cardiovascular or cerebrovascular disease.
- Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease).
- Child-Pugh B/C liver cirrhosis.
- History of prior or current malignancy.
- HIV positive
- History of progressive multifocal leukoencephalopathy (PML).
- Active hepatitis B or C infection:
- Corticosteroid use \> 20 mg within 1 week before the first dose of study intervention.
- History of hypersensitivity or anaphylaxis to study intervention(s).
- Requires treatment with a strong CYP3A4 inhibitor/inducer.
- Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists.
- Major surgical procedure within 30 days of the first dose of study intervention.
Where
- Boston, Massachusetts
- Charlotte, North Carolina
- Durham, North Carolina
- Winston-Salem, North Carolina
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 2, 2026 · Source of record for eligibility and locations